These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1050 related articles for article (PubMed ID: 32343640)

  • 21. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
    El-Khoueiry AB; Sangro B; Yau T; Crocenzi TS; Kudo M; Hsu C; Kim TY; Choo SP; Trojan J; Welling TH; Meyer T; Kang YK; Yeo W; Chopra A; Anderson J; Dela Cruz C; Lang L; Neely J; Tang H; Dastani HB; Melero I
    Lancet; 2017 Jun; 389(10088):2492-2502. PubMed ID: 28434648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study.
    Overman MJ; Gelsomino F; Aglietta M; Wong M; Limon Miron ML; Leonard G; García-Alfonso P; Hill AG; Cubillo Gracian A; Van Cutsem E; El-Rayes B; McCraith SM; He B; Lei M; Lonardi S
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38821718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers.
    Hellmann MD; Sturm I; Trnkova ZJ; Lettieri J; Diefenbach K; Rizvi NA; Gettinger SN
    Clin Lung Cancer; 2015 Nov; 16(6):514-22. PubMed ID: 26003007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study.
    Xu J; Zhang Y; Jia R; Yue C; Chang L; Liu R; Zhang G; Zhao C; Zhang Y; Chen C; Wang Y; Yi X; Hu Z; Zou J; Wang Q
    Clin Cancer Res; 2019 Jan; 25(2):515-523. PubMed ID: 30348638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer.
    Wang C; Chevalier D; Saluja J; Sandhu J; Lau C; Fakih M
    Oncologist; 2020 Aug; 25(8):e1188-e1194. PubMed ID: 32406541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer.
    Patel MR; Falchook GS; Hamada K; Makris L; Bendell JC
    Cancer Med; 2021 Feb; 10(4):1183-1190. PubMed ID: 33544407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.
    Pavlakis N; Sjoquist KM; Martin AJ; Tsobanis E; Yip S; Kang YK; Bang YJ; Alcindor T; O'Callaghan CJ; Burnell MJ; Tebbutt NC; Rha SY; Lee J; Cho JY; Lipton LR; Wong M; Strickland A; Kim JW; Zalcberg JR; Simes J; Goldstein D
    J Clin Oncol; 2016 Aug; 34(23):2728-35. PubMed ID: 27325864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan.
    Hirano G; Makiyama A; Makiyama C; Esaki T; Oda H; Uchino K; Komoda M; Tanaka R; Matsushita Y; Mitsugi K; Shibata Y; Kumagai H; Arita S; Ariyama H; Kusaba H; Akashi K; Baba E
    Anticancer Res; 2015 Jan; 35(1):371-7. PubMed ID: 25550574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer.
    Nakajima TE; Kadowaki S; Minashi K; Nishina T; Yamanaka T; Hayashi Y; Izawa N; Muro K; Hironaka S; Kajiwara T; Kawakami Y
    Clin Cancer Res; 2021 Feb; 27(4):1029-1036. PubMed ID: 33262133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-PD-1 and regorafenib induce severe multisystem adverse events in microsatellite stability metastatic colorectal cancer: a case report.
    Yang Y; Xu L; Wang D; Hui B; Li X; Zhou Y; Chen X; Gu Y
    Immunotherapy; 2021 Nov; 13(16):1317-1323. PubMed ID: 34369830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
    Sanoff HK; Goldberg RM; Ivanova A; O'Reilly S; Kasbari SS; Kim RD; McDermott R; Moore DT; Zamboni W; Grogan W; Cohn AL; Bekaii-Saab TS; Leonard G; Ryan T; Olowokure OO; Fernando NH; McCaffrey J; El-Rayes BF; Horgan AM; Sherrill GB; Yacoub GH; O'Neil BH
    Cancer; 2018 Aug; 124(15):3118-3126. PubMed ID: 29905927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
    Duffaud F; Mir O; Boudou-Rouquette P; Piperno-Neumann S; Penel N; Bompas E; Delcambre C; Kalbacher E; Italiano A; Collard O; Chevreau C; Saada E; Isambert N; Delaye J; Schiffler C; Bouvier C; Vidal V; Chabaud S; Blay JY;
    Lancet Oncol; 2019 Jan; 20(1):120-133. PubMed ID: 30477937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).
    Carrato A; Benavides M; Massutí B; Ferreiro-Monteagudo R; García Alfonso P; Falcó E; Reboredo M; Cano T; Gallego J; Viéitez JM; Layos L; Salud A; Polo E; Dotor E; Durán-Ogalla G; Rodriguez-Garrote M; Calvo A; Grande E; Aranda E
    BMC Cancer; 2019 Jun; 19(1):533. PubMed ID: 31159765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy.
    Marks EI; Tan C; Zhang J; Zhou L; Yang Z; Scicchitano A; El-Deiry WS
    Cancer Biol Ther; 2015; 16(12):1710-9. PubMed ID: 26561209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase 1 study of regorafenib and sildenafil in adults with advanced solid tumors.
    Poklepovic AS; Gordon SW; Kothadia S; McGuire WP; Thacker LR; Deng X; Tombes MB; Shrader E; Hudson D; Bandyopadhyay D; Ryan AA; Kmieciak M; Smith S; Dent P
    Anticancer Drugs; 2024 Jun; 35(5):450-458. PubMed ID: 38452059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE.
    Cartwright E; Slater S; Saffery C; Tran A; Turkes F; Smith G; Aresu M; Kohoutova D; Terlizzo M; Zhitkov O; Rana I; Johnston EW; Sanna I; Smyth E; Mansoor W; Fribbens C; Rao S; Chau I; Starling N; Cunningham D
    ESMO Open; 2024 Apr; 9(4):102971. PubMed ID: 38518549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
    García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
    Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors.
    Doi T; Muro K; Ishii H; Kato T; Tsushima T; Takenoyama M; Oizumi S; Gemmoto K; Suna H; Enokitani K; Kawakami T; Nishikawa H; Yamamoto N
    Clin Cancer Res; 2019 Nov; 25(22):6614-6622. PubMed ID: 31455681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
    Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
    Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.